(株)ケイファーマの貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|
| 東証GRT | 医薬品 | 4896/ - | - |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|
| 2024/09/20 | 日証協 | 70,400株 | -0.14% | 1,400株 | +100% | 135,130株 | +1.2% | 1,800株 | +12.5% |
| 2024/09/13 | 日証協 | 70,500株 | -8.8% | 700株 | -36.36% | 133,530株 | -1.69% | 1,600株 | 0% |
| 2024/09/06 | 日証協 | 77,300株 | -0.9% | 1,100株 | -73.17% | 135,830株 | +0.67% | 1,600株 | +22.98% |
| 2024/08/30 | 日証協 | 78,000株 | -3.11% | 4,100株 | -66.94% | 134,930株 | +5.8% | 1,301株 | -93.23% |
| 2024/08/23 | 日証協 | 80,500株 | -0.37% | 12,400株 | +10.71% | 127,529株 | -1.09% | 19,210株 | +540.33% |
| 2024/08/16 | 日証協 | 80,800株 | +2.15% | 11,200株 | -44.83% | 128,929株 | +0.7% | 3,000株 | -77.27% |
| 2024/08/09 | 日証協 | 79,100株 | -6.39% | 20,300株 | +222.22% | 128,029株 | -1.69% | 13,200株 | +149.06% |
| 2024/08/02 | 日証協 | 84,500株 | -27.9% | 6,300株 | +43.18% | 130,229株 | -11.91% | 5,300株 | -8.64% |
| 2024/07/26 | 日証協 | 117,200株 | -13.38% | 4,400株 | -38.89% | 147,829株 | -5.56% | 5,801株 | -21.61% |
| 2024/07/19 | 日証協 | 135,300株 | -16.74% | 7,200株 | -63.64% | 156,528株 | -15.22% | 7,400株 | -42.19% |
| 2024/07/12 | 日証協 | 162,500株 | +3.83% | 19,800株 | -43.27% | 184,628株 | -0.27% | 12,800株 | -48.19% |
| 2024/07/05 | 日証協 | 156,500株 | +3.85% | 34,900株 | -4.38% | 185,128株 | +6.5% | 24,707株 | -8.5% |
| 2024/06/28 | 日証協 | 150,700株 | +19.22% | 36,500株 | +16.24% | 173,827株 | -0.97% | 27,002株 | +28.53% |
| 2024/06/21 | 日証協 | 126,400株 | -9.71% | 31,400株 | -49.27% | 175,526株 | +1.2% | 21,008株 | -73.61% |
| 2024/06/14 | 日証協 | 140,000株 | -1.89% | 61,900株 | +1189.58% | 173,449株 | +6.97% | 79,600株 | +410.26% |
| 2024/06/07 | 日証協 | 142,700株 | -4.68% | 4,800株 | -40% | 162,153株 | -7.32% | 15,600株 | +766.67% |
| 2024/05/31 | 日証協 | 149,700株 | -7.36% | 8,000株 | +1042.86% | 174,953株 | -7.06% | 1,800株 | -30.77% |
| 2024/05/24 | 日証協 | 161,600株 | -11.89% | 700株 | -85.71% | 188,253株 | -5.9% | 2,600株 | +13.04% |
| 2024/05/17 | 日証協 | 183,400株 | -4.03% | 4,900株 | +63.33% | 200,053株 | -2.25% | 2,300株 | +283.33% |
※株式分割は考慮していませんのでご注意ください。
Page Top